

- (ii) Permanent and temporary deferrals for health reasons including reason(s) for deferral.
 - (iii) Donor adverse reaction complaints and reports, including results of all investigations and followup.
 - (iv) Therapeutic bleedings, including signed requests from attending physicians, the donor's disease and disposition of units.
 - (v) Immunization, including informed consent, identification of the antigen, dosage and route of administration.
 - (vi) Blood collection, including identification of the phlebotomist.
 - (vii) Records to relate the donor with the unit number of each previous donation from that donor.
 - (viii) Records of quarantine, notification, testing, and disposition performed pursuant to §§ 610.46 and 610.47 of this chapter.
- (2) Processing records:
- (i) Blood processing, including results and interpretation of all tests and retests.
 - (ii) Component preparation, including all relevant dates and times.
 - (iii) Separation and pooling of recovered plasma.
 - (iv) Centrifugation and pooling of source plasma.
 - (v) Labeling, including initials of person(s) responsible.
- (3) Storage and distribution records:
- (i) Distribution and disposition, as appropriate, of blood and blood products.
 - (ii) Visual inspection of whole blood and red blood cells during storage and immediately before distribution.
 - (iii) Storage temperature, including initialed temperature recorder charts.
 - (iv) Reissue, including records of proper temperature maintenance.
 - (v) Emergency release of blood, including signature of requesting physician obtained before or after release.
- (4) Compatibility test records:
- (i) Results of all compatibility tests, including crossmatching, testing of patient samples, antibody screening and identification.
 - (ii) Results of confirmatory testing.
- (5) Quality control records:
- (i) Calibration and standardization of equipment.
 - (ii) Performance checks of equipment and reagents.
 - (iii) Periodic check on sterile technique.
 - (iv) Periodic tests of capacity of shipping containers to maintain proper temperature in transit.
 - (v) Proficiency test results.
 - (6) Transfusion reaction reports and complaints, including records of investigations and followup.
 - (7) General records:
 - (i) Sterilization of supplies and reagents prepared within the facility, including date, time interval, temperature and mode.
 - (ii) Responsible personnel.
 - (iii) Errors and accidents.
 - (iv) Maintenance records for equipment and general physical plant.
 - (v) Supplies and reagents, including name of manufacturer or supplier, lot numbers, expiration date and date of receipt.
 - (vi) Disposition of rejected supplies and reagents used in the collection, processing and compatibility testing of blood and blood components.
 - (c) A donor number shall be assigned to each accepted donor, which relates the unit of blood collected to that donor, to his medical record, to any component or blood product from that donor's unit of blood, and to all records describing the history and ultimate disposition of these products.
 - (d) Records shall be retained for such interval beyond the expiration date for the blood or blood component as necessary to facilitate the reporting of any unfavorable clinical reactions. The retention period shall be no less than 5 years after the records of processing have been completed or 6 months after the latest expiration date for the individual product, whichever is a later date. When there is no expiration date, records shall be retained indefinitely.
 - (e) A record shall be available from which unsuitable donors may be identified so that products from such individuals will not be distributed.
- [40 FR 53532, Nov. 18, 1975, as amended at 61 FR 47422, Sept. 9, 1996]

§ 606.165 Distribution and receipt; procedures and records.

- (a) Distribution and receipt procedures shall include a system by which the distribution or receipt of each unit

can be readily determined to facilitate its recall, if necessary.

(b) Distribution records shall contain information to readily facilitate the identification of the name and address of the consignee, the date and quantity delivered, the lot number of the unit(s), the date of expiration or the date of collection, whichever is applicable, or for crossmatched blood and blood components, the name of the recipient.

(c) Receipt records shall contain the name and address of the collecting facility, date received, donor or lot number assigned by the collecting facility and the date of expiration or the date of collection, whichever is applicable.

§ 606.170 Adverse reaction file.

(a) Records shall be maintained of any reports of complaints of adverse reactions regarding each unit of blood or blood product arising as a result of blood collection or transfusion. A thorough investigation of each reported adverse reaction shall be made. A written report of the investigation of adverse reactions, including conclusions and followup, shall be prepared and maintained as part of the record for that lot or unit of final product by the collecting or transfusing facility. When it is determined that the product was at fault in causing a transfusion reaction, copies of all such written reports shall be forwarded to and maintained by the manufacturer or collecting facility.

(b) When a complication of blood collection or transfusion is confirmed to be fatal, the Director, Office of Compliance, Center for Biologics Evaluation and Research, shall be notified by telephone or telegraph as soon as possible; a written report of the investigation shall be submitted to the Director, Office of Compliance, Center for Biologics Evaluation and Research, within 7 days after the fatality by the collecting facility in the event of a donor reaction, or by the facility that performed the compatibility tests in the event of a transfusion reaction.

(Information collection requirements approved by the Office of Management and Budget under control number 0910-0116)

[40 FR 53532, Nov. 18, 1975, as amended at 49 FR 23833, June 8, 1984; 50 FR 35471, Aug. 30, 1985; 55 FR 11014, Mar. 26, 1990]

PART 607—ESTABLISHMENT REGISTRATION AND PRODUCT LISTING FOR MANUFACTURERS OF HUMAN BLOOD AND BLOOD PRODUCTS

Subpart A—General Provisions

Sec.

607.3 Definitions.

607.7 Establishment registration and product listing of blood banks and other firms manufacturing human blood and blood products.

Subpart B—Procedures for Domestic Blood Product Establishments

607.20 Who must register and submit a blood product list.

607.21 Times for establishment registration and blood product listing.

607.22 How and where to register establishments and list blood products.

607.25 Information required for establishment registration and blood product listing.

607.26 Amendments to establishment registration.

607.30 Updating blood product listing information.

607.31 Additional blood product listing information.

607.35 Notification of registrant; blood product establishment registration number and NDC Labeler Code.

607.37 Inspection of establishment registrations and blood product listings.

607.39 Misbranding by reference to establishment registration or to registration number.

Subpart C—Procedures for Foreign Blood Product Establishments

607.40 Blood product listing requirements for foreign blood product establishments.

Subpart D—Exemptions

607.65 Exemptions for blood product establishments.

AUTHORITY: 21 U.S.C. 321, 331, 351, 352, 355, 360, 371, 374; 42 U.S.C. 216, 262.

SOURCE: 40 FR 52788, Nov. 12, 1975, unless otherwise noted.

Subpart A—General Provisions

§ 607.3 Definitions.

(a) The term *act* means the Federal Food, Drug, and Cosmetic Act approved June 25, 1938 (52 Stat. 1040 et seq., as amended, 21 U.S.C. 301-392).